Riley R J, Leeder J S
Department of Drug Metabolism and Pharmacokinetics, Fisons Pharmaceuticals Plc, Loughborough, UK.
Clin Exp Immunol. 1995 Jan;99(1):1-6. doi: 10.1111/j.1365-2249.1995.tb03463.x.
Idiosyncratic hypersensitivity reactions may account for up to 25% of all adverse reactions, and pose a constant problem to physicians because of their unpredictable nature, potentially fatal outcome and resemblance to other disease processes. Current understanding of how drug allergy arises is based largely on the hapten hypothesis: since most drugs are not chemically reactive per se, they must be activated metabolically to reactive species which may become immunogenic through interactions with cellular macromolecules. The role of drug metabolism is thus pivotal to the hapten hypothesis both in activation of the parent compound and detoxification of the reactive species. Although conjugation reactions may occasionally produce potential immunogens (for example, the generation of acylglucuronides from non-steroidal anti-inflammatory drugs such as diclofenac), bioactivation is catalysed most frequently by cytochrome P450 (P450) enzymes. The multifactorial nature of hypersensitivity reactions, particularly the role of often unidentified, reactive drug metabolites in antigen generation, has hampered the routine diagnosis of these disorders by classical immunological methods designed to detect circulating antibodies or sensitized T cells. Similarly, species differences in drug metabolism and immune system regulation have largely precluded the establishment of appropriate animal models with which to examine the immunopathological mechanisms of these toxicities. However, the combined use of in vitro toxicity assays incorporating human tissues and in vivo phenotyping (or, ultimately, in vitro genotyping) methods for drug detoxification pathways may provide the metabolic basis for hypersensitivity reactions to several drugs. This brief review highlights recent efforts to unravel the bases for hypersensitivity reactions to these therapeutic agents (which include anticonvulsants and sulphonamides) using drug metabolism and immunochemical approaches. In particular, examples are provided which illustrate breakthroughs in the identification of the chemical nature of the reactive metabolites which become bound to cellular macromolecules, the enzyme systems responsible for their generation and (possibly) detoxification, and the target proteins implicated in the subsequent immune response.
特异质超敏反应可能占所有不良反应的25%,因其不可预测的性质、潜在的致命后果以及与其他疾病过程的相似性,给医生带来了持续的难题。目前对药物过敏如何产生的理解很大程度上基于半抗原假说:由于大多数药物本身没有化学反应性,它们必须通过代谢激活成为反应性物质,这些物质可能通过与细胞大分子相互作用而具有免疫原性。因此,药物代谢在半抗原假说中对于母体化合物的激活和反应性物质的解毒都至关重要。尽管结合反应偶尔可能产生潜在的免疫原(例如,从双氯芬酸等非甾体抗炎药生成酰基葡萄糖醛酸),但生物激活最常由细胞色素P450(P450)酶催化。超敏反应的多因素性质,特别是通常未明确的反应性药物代谢物在抗原产生中的作用,阻碍了通过旨在检测循环抗体或致敏T细胞的经典免疫学方法对这些疾病进行常规诊断。同样,药物代谢和免疫系统调节方面的物种差异在很大程度上排除了建立合适的动物模型来研究这些毒性的免疫病理机制。然而,结合使用包含人体组织的体外毒性测定和用于药物解毒途径的体内表型分析(或最终的体外基因分型)方法,可能为几种药物的超敏反应提供代谢基础。这篇简短的综述强调了最近利用药物代谢和免疫化学方法来揭示对这些治疗药物(包括抗惊厥药和磺胺类药物)超敏反应基础的努力。特别是,提供了一些例子,说明了在鉴定与细胞大分子结合的反应性代谢物的化学性质、负责其生成和(可能)解毒的酶系统以及参与后续免疫反应的靶蛋白方面取得的突破。